SC: SARFAESI Act Was Not Applicable in Nagaland Before its 2021 Adoption, Dismisses Creditor’s Plea || SC: Lis Pendens Applies To Money Suits on Mortgaged Property, Including Ex Parte Proceedings || Kerala HC: Civil Courts Cannot Grant Injunctions in NCLT Matters and Such Orders Can Be Set Aside || Bombay High Court: Technical Breaks to Temporary Employees Cannot Deny Maternity Leave Benefits || NCLAT: Appellate Jurisdiction Limited to Orders Deciding Parties’ Rights, Not Procedural Directions || NCLAT: Personal Guarantors Involved In NCLT Proceedings Can Appeal Against Insolvency Admission || Supreme Court: Foreign Companies’ Head Office Expenses in India are Capped under Section 44C || SC Directs Trial Courts to Systematically Catalogue Witnesses and Evidence in Criminal Judgments || SC Calls For Sensitising Future Generations on Equality in Marriage to Combat Dowry Practices || SC: Separate Suits Against Confirmed Auction Sales are Barred; Remedy Available under Sec 47

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :